论文部分内容阅读
目的 探讨卵巢上皮癌bcl—2、p53基因与肿瘤多药耐药的相关关系。方法 用免疫组化LSAB法检测70例卵巢上皮癌和15例交界瘤的bcl—2、p53基因水平的表达。结果 卵巢癌的bcl—2基因水平呈低表达,浆液性癌、粘液性癌的bcl—2基因表达率分别为11％(5/45)和20％(5/25),交界瘤呈阴性反应。p53抑制基因在浆液性癌、粘液性癌和交界瘤的表达率则分别为77％、72％和0％,P—gp基因在卵巢癌呈高表达,上述三类标本的阳性率分别为88％、80％及33％。结论 bcl—2与p53基因水平的表达与肿瘤细胞的多药耐药相关,bcl—2可作为预测肿瘤预后及药物敏感性的重要指标之一。
Objective To investigate the relationship between the expression of bcl-2 and p53 genes and multidrug resistance in epithelial ovarian cancer. Methods The expression of bcl-2 and p53 genes in 70 cases of epithelial ovarian cancer and 15 cases of borderline tumor were detected by immunohistochemical LSAB method. Results The expression of bcl-2 gene was low in ovarian cancer. The rates of bcl-2 gene expression in serous and mucinous cancers were 11% (5/45) and 20% (5/25), respectively. The borderline tumors were negative . The expression rates of p53 suppressor gene in serous carcinoma, mucinous carcinoma and borderline tumor were 77%, 72% and 0%, respectively. The expression of P-gp gene in ovarian cancer was high, the positive rates of the three types of specimens were 88 %, 80% and 33%. Conclusion The expression of bcl-2 and p53 genes is related to multidrug resistance in tumor cells. Bcl-2 may be one of the important indexes in predicting tumor prognosis and drug sensitivity.